Alzheimer's disease (AD) is a debilitating neurodegenerative disorder characterized by increased b-amyloid (Ab) deposition and neuronal dysfunction leading to impaired learning and recall. Ageing, heredity, and induced oxidative stress are among proposed risk factors. The increased frequency of the disease in women also suggests a role for estrogen in development of AD. In the present study, effects of the phytoestrogen genistein (10 mg/kg) on learning and memory impairments was assessed in intrahippocampal Ab (1-40) -injected rats. The estrogen receptor antagonist fulvestrant was injected intracerebroventricularly in a group of Ab-lesioned rats. The Ab-injected animals exhibited the following: lower spontaneous alternation score in Y-maze tasks, impaired retention and recall capability in the passive avoidance test, and fewer correct choices and more errors in the RAM task. Genistein, but not genistein and fulvestrant, significantly improved most of these parameters. Measurements of oxidative stress markers in hippocampal tissue of Ab-injected rats showed an elevation of malondialdehyde (MDA) and nitrite content, and a reduction of superoxide dismutase (SOD) activity. Genistein significantly attenuated the increased MDA content but did not affect the nitrite content or SOD activity. These results indicate that genistein pretreatment ameliorates Ab-induced impairment of shortterm spatial memory in rats through an estrogenic pathway and by inducing attenuation of oxidative stress.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that gradually impairs memory and the ability to learn, make judgments, communicate with others, and carry out daily activities (reviewed by Stuchbury and Munch (2005) ). It has been estimated that about 5% of the population older than 65 years is affected by AD (reviewed by Shah et al. (2008) ). There is also evidence that the number of dementia cases in Europe will reach almost 6 million in 2010 and around 14 million in 2050 (Mura, Dartigues, & Berr, 2010) , and 80% of those individuals may suffer from AD (Jellinger & Attems, 2010) . Furthermore, a report from the United States has predicted that the annual incidence of the disease will increase from 337,000 cases in 1995 to 959,000 in 2050 (Hebert, Beckett, Scherr, & Evans, 2001 ). This projection certainly indicates the magnitude of the problem in terms of the high number of suffering patients, the pressure on their relatives, and the negative socioeconomic outcomes of AD.
In the course of the disease, short-term memory is affected first due to neuronal dysfunction and degeneration in the hippocampus and amygdala. Neuropathological hallmarks of AD include deposition of b-amyloid (Ab)-containing senile plaques and the presence of intracellular neurofibrillary tangles in hippocampal and cerebral cortical regions (reviewed by Munch et al. (1998) and Retz, Gsell, Munch, Rosler, and Riederer (1998)). The pathogenic mechanisms underlying AD include impaired cholinergic function, increased oxidative stress, induction of the amyloid cascade (i.e., Ab deposition and plaque formation), expression of inflammatory mediators, deficiencies in steroid hormones, and appearance of glutamatemediated excitotoxicity (reviewed by Shah et al. (2008) ). Of all these, the amyloid cascade hypothesis suggesting a pivotal role for Ab in the pathogenesis of AD is the mechanism that is accepted by most investigators in this field (reviewed by Klafki, Staufenbiel, Kornhuber, and Wiltfang (2006) ). As mentioned, increased oxidative stress due to lipid peroxidation, protein oxidation, and the formation of hydrogen peroxide may also be involved in Ab-induced neurotoxicity (reviewed by Butterfield and Lauderback (2002) ). Indeed, in studies based on that assumption, it was found that antioxidant therapy prevented the learning and memory deficits induced by Ab in rats (Yamada et al., 1999) , and it also delayed the clinical progression of the disease in humans (Sano et al., 
